HC Wainwright Comments on Mural Oncology Q1 Earnings

Mural Oncology plc (NASDAQ:MURA) – HC Wainwright issued their Q1 2026 earnings per share estimates for Mural Oncology in a report issued on Wednesday, March 26th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($3.32) EPS.

A number of other equities research analysts also recently issued reports on MURA. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research report on Tuesday. Morgan Stanley cut Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday. Finally, Raymond James downgraded Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price on the stock. in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Trading Down 12.6 %

MURA stock opened at $1.18 on Friday. The company’s 50-day moving average price is $3.72 and its 200 day moving average price is $3.57. Mural Oncology has a 52 week low of $1.12 and a 52 week high of $5.02. The company has a market cap of $20.33 million, a P/E ratio of -0.13 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the prior year, the firm posted ($3.57) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Acorn Capital Advisors LLC purchased a new stake in Mural Oncology in the 4th quarter valued at approximately $4,141,000. Renaissance Technologies LLC raised its holdings in shares of Mural Oncology by 17.4% in the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after acquiring an additional 35,403 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Mural Oncology by 2.6% in the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Mural Oncology by 1.4% during the fourth quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock valued at $565,000 after acquiring an additional 2,470 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Mural Oncology during the 3rd quarter worth about $340,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.